Table 1.
Experimental design for the immunogenicity study in pigs of Langerin-targeted PEDV vaccine.
No. | Treatment groups | Antigen dose |
Adjuvant dose | Vaccine Volume | Prime route (single site) | Booster route (single site) | No. of pigs |
---|---|---|---|---|---|---|---|
1 | Adjuvant Control | – | 50 μg | 250 μL | Transdermal | Intramuscular | 8 |
2 | Non-targeted PEDVsAg | 200 μg | 50 μg | 250 μL | Transdermal | Intramuscular | 8 |
3 | Langerin-targeted PEDVsAg | 200 μg | 50 μg | 250 μL | Transdermal | Intramuscular | 8 |
4 | Langerin-targeted PEDVsAg | 200 μg | 50 μg | 250 μL | Intramuscular | Intramuscular | 7 |